• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Infectious Disease

HIV exposure and infection affect neurodevelopmental outcomes in young children

byShyam AkulaandCordelia Ross
January 26, 2018
in Infectious Disease, Pediatrics, Public Health
Reading Time: 3 mins read
Ultrasound enhances gastrointestinal absorption of drugs at low frequencies
Share on FacebookShare on Twitter

1. Children less than 8 years old infected with HIV and children who were HIV exposed-but-uninfected had poorer neurodevelopmental outcomes compared to unexposed children.

2. Those children who were either HIV-infected or exposed-but-uninfected who also had anti-retroviral exposure may have lower neuropsychological function than those without anti-retroviral exposure.

Evidence Rating Level: 2 (Good)

Study Rundown: HIV infection is known to result in worse neurodevelopmental outcomes in children born to HIV-infected mothers. However, less is known about the outcomes of children who are HIV exposed-but-uninfected (HEU), as well as the impact of anti-retroviral (ARV) exposure on neurodevelopment. In this study, authors conducted a systematic review and meta-analysis of literature pertaining to neurodevelopmental outcomes of children born to HIV-infected mothers. They reviewed 45 studies, 11 of which were used for meta-analysis. Neurodevelopmental outcomes were measured using a standardized neuropsychological assessment tool, the Bayley Scales of Infant and Toddler Development (BSID). HIV infected (HIV+) children and HEU children showed worse cognitive and motor outcomes compared with uninfected (HUU) children, and HEU children showed better outcomes compared to HIV+ children. Furthermore, ARV exposure may also be associated with poorer developmental outcomes, but further data in this area is necessary. Overall, this meta-analysis is a comprehensive, standardized comparison of neurodevelopmental outcomes in these 3 groups of children; however, results were limited by study heterogeneity, and confounders such as location were not controlled for. Overall, this study provides the first, quantitative analysis of neurodevelopment outcomes in HIV-exposed children. This study points to the necessity for more data regarding ARV exposure in the perinatal period. Findings also provide a baseline for efforts to improve neurodevelopmental outcomes in a vulnerable population.

Click to read the study, published today in Pediatrics 

Relevant Reading: Health and survival of HIV perinatally exposed but uninfected children born to HIV-infected mothers

RELATED REPORTS

Weekly islatravir plus lenacapavir maintains HIV virologic suppression

Ending Ryan White services may increase human immunodeficiency virus incidence

Anal cancer screening cost-effective for men who have sex with men with human immunodeficiency virus aged above 35 years

In-Depth [systematic review and meta-analysis]: This meta-analysis reviewed 45 studies, 11 of which were included in a network meta-analysis that met the authors’ criteria. Studies were included based on the use of a standardized neuropsychological assessment (BSID), an age cutoff of 8 years old for subjects, and lack of significant confounding factors. HUU children were used as the statistical reference group. Systematic heterogeneity was assessed with subgroup analysis and meta-regression, and studies were analyzed for their quality, with sub-analyses based on quality ratings. Adjusted meta regression results of both measurements of the Mental Developmental Index (MDI), as well as the Psychomotor Developmental Index (PDI) from within the BSID showed HIV+ children having poorer outcomes than HUU children on both scales (MDI: -16.3 points, 95% CI: [-26.2, -7.1]; PDI: -17.62 points, 95% CI: [-27.3, -7.6]). HEU children showed lower outcomes to a lesser extent (MDI: -6.61 points, 95% CI: [-15.5, 2.54]; PDI: -4.25 points, 95% CI: [-13.71, 5.12]). Measuring the effect of ARV exposure on BSID scores for HIV+ and HEU children suggested a possible effect of ARVs: exposed children had lower mean scores than those unexposed to ARVs in both subdomains of the BSID examined, compared to HUU children (MDI: [HEU: -10.0 vs. 0.95, HIV+: -20.3 vs -7.8]); (PDI: [HEU: -5.5 vs. -1.2, HIV+: -19.4 vs -12.7]).

Image: CC

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: antiretroviralHIV/AIDShuman immunodeficiency virus (HIV)
Previous Post

Shorter duration of glecaprevir-pibrentasvir effective against hepatitis C virus: The ENDURANCE trials

Next Post

The PARADIGM-HF trial: Valsartan-neprilysin inhibitor vs. enalapril in patients with heart failure [Classic Series]

RelatedReports

Few high school students, young adults get HIV testing
Chronic Disease

Weekly islatravir plus lenacapavir maintains HIV virologic suppression

December 22, 2025
Institute of Medicine identifies cost variation between geographic regions
Infectious Disease

Ending Ryan White services may increase human immunodeficiency virus incidence

September 8, 2025
Government-funded initiatives provide important supports to low-income HIV patients
Infectious Disease

Anal cancer screening cost-effective for men who have sex with men with human immunodeficiency virus aged above 35 years

June 16, 2025
Combined immunotherapy may improve survival in metastatic pancreatic cancer
Infectious Disease

Safety of investigational vaccines against human immunodeficiency virus

April 29, 2025
Next Post
Adverse pregnancy outcomes associated with thrombophilias [Classics Series]

The PARADIGM-HF trial: Valsartan-neprilysin inhibitor vs. enalapril in patients with heart failure [Classic Series]

Greater rates of mortality linked to infants at risk for maltreatment

Free alternatives comparable to Mini-Mental State Examination

2 Minute Medicine Rewind January 29, 2018

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • The rate of urethrocutaneous fistula following caudal and penile blocks for hypospadias repair may be similar
  • Adjuvant chemotherapy not linked to improved outcomes in localized appendiceal adenocarcinoma
  • Deep learning model improved cancer recurrence prediction for pediatric glioma using serial imaging
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.